Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Longevity · Dosing reference

FOXO4-DRI dosage

What the human evidence does and does not show, how long studies ran, and the arithmetic for working with vials.

Not approved — research use onlyCPreclinical researchNone established
Full research pageCycle-length evidenceComparePrefer Amiravo on Google
Regulatory status
Not approved — research use only
Human amounts
None established in humans
Route studied
—
Frequency
Not established
Half-life
Not established
Evidence grade
Grade C · Preclinical research
Vial sizes on the market
10 mg
Other forms seen
—

What FOXO4-DRI is

A synthetic D-retro-inverso peptide that disrupts FOXO4 and p53 interaction, studied in senescent cell research.

In senescent cells, FOXO4 has been reported to associate with p53 and keep it in the nucleus, which was described as maintaining viability and suppressing apoptosis in those cells 1,7. FOXO4-DRI was designed as a competing peptide: in cell experiments it caused p53 nuclear exclusion and apoptosis selectively in senescent cells 1. Structural basis A 2025 NMR study reported that both FOXO4 and FOXO4-DRI target the… How it works →

Key evidence

  • Baar et al., Cell · 2017 · Cells, then mice (doxorubicin chemotoxicity; XpdTTD/TTD fast-ageing and naturally aged animals)
    A designed FOXO4-interfering peptide caused p53 nuclear exclusion and apoptosis selectively in senescent cells and, in mice, was associated with counteraction of chemotoxicity and with restored fitness, fur density and renal function. 1
  • Zhang et al., Aging (Albany NY) · 2020 · Human tissue, TM3 Leydig cells, naturally aged mice
    Reported selective apoptosis of senescent Leydig cells and, in naturally aged mice, an improved testicular microenvironment and alleviation of age-related testosterone secretion insufficiency. 8
  • Born et al., Circulation · 2023 · Human lung tissue, mice (including serotonin-transporter overexpressing) and rats
    Elimination of senescent pulmonary endothelial cells, including with FOXO4-DRI, was associated with worsened pulmonary haemodynamics and loss of pulmonary endothelial cells, leading the authors to caution about senolytic strategies. 10
All studies on the research page

What the human evidence shows

No approved or established human dose

We searched PubMed and ClinicalTrials.gov and found no human studies that administered FOXO4-DRI. The research described on its page is from cells or animals, and animal amounts do not translate to people.

How long did human studies run?

No human study durations are recorded for FOXO4-DRI.

Cycle-length evidence for FOXO4-DRI

FOXO4-DRI draw calculator

Pick the vial strength and the water added, enter an amount, and see the concentration, the units to draw and how many draws the vial holds. Arithmetic only.

1 · Vial strength
sizes on the market
2 · Water added
3 · Amount per draw
4 · Syringe
Your mix
10 mg + 2 mL water = 5 mg/mL
10 units holds 0.5 mg (500 mcg)
Draw toEnter an amount in step 3
0102030405060708090100
U-100 syringe · 100 units = 1 mL

Computed from your inputs. Not a dose or a recommendation.

Compare water volumes for this vialShow

More water = lower concentration = a larger, easier-to-measure draw. Tap a row to use it.

Watermg/mLDraw
0.5 mL20—
1 mL10—
1.5 mL6.667—
2 mL5—
2.5 mL4—
3 mL3.333—
5 mL2—

Supplies and handling

  • Lyophilized vial
    Sealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
  • Sterile diluent
    The diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
  • Graduated syringes
    Sized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
  • Alcohol prep pads
    For wiping vial stoppers before each puncture.
  • Nitrile gloves
    Clean gloves for aseptic handling.
  • Sharps container
    Puncture-resistant container for used needles.
Step-by-step reconstitution guideStorage and transport accessories

Storage

General research-context handling only. Lyophilized synthetic peptides are typically held cold and protected from light and moisture, and reconstituted material is less stable than lyophilized material; defer to the supplier's own stability and handling documentation for the specific lot. No preparation or administration instructions are given on this page.

  • Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
  • Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
  • Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.

Handling mistakes and troubleshooting

Added the wrong volume of diluent
The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.
Shook the vial and it foamed
Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.
The solution is cloudy or has particles
Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.
The powder cake looks melted or shrunken before reconstitution
This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.
Liquid sprayed back when the needle was removed
Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.

Regulatory status

Status
Not approved by the FDA for any use, and no DailyMed drug label for it was found 3,4. No registered clinical trial of FOXO4-DRI was identified in a ClinicalTrials.gov search, which returned no studies for the term 5. It does not appear in any category of FDA's May 14, 2026 503A bulk drug substances list 6.
United States (FDA)
No approved FDA application exists for FOXO4-DRI, and a DailyMed name search returned no label 3,4. The compound does not appear in category 1, 2 or 3 of FDA's May 14, 2026 503A bulk drug substances list, so it has no recognised position in that compounding framework 6. No registered clinical trial was identified on ClinicalTrials.gov 5.
Sport (WADA)
FOXO4-DRI is not named anywhere in the WADA 2026 Prohibited List 16. That is hedged negative evidence, not a clearance: section S0, Non-Approved Substances, prohibits at all times any pharmacological substance not addressed by a later section and with no current approval by any governmental regulatory health authority for human therapeutic use, and introduces its named examples with "including but not limited to" 16. A substance with no approval anywhere and no section of its own is the situation S0 is written to cover, so an athlete should not read the absence of the name as permission 16.

Status varies by country and changes over time. How we describe regulatory status.

FOXO4-DRI compared with related compounds

CompoundStatusEvidenceHuman amountsHalf-life
FOXO4-DRINot approved — research use onlyCNone established—
Methylene BlueFDA-approvedAFDA labelApproximately 24 hours
L-GlutathioneNot approved — research use onlyBNone established—
EpithalonNot approved — research use onlyCNone established—
N-Acetyl Epithalon AmidateNot approved — research use only—None established—
NAD+Not approved — research use onlyBNone established—

Frequently asked questions

What doses of FOXO4-DRI have been studied in humans?
None that establish an amount. FOXO4-DRI is not approved anywhere and we found no human studies that administered it. Amiravo does not publish community or vendor figures.
Is there an established FOXO4-DRI cycle length?
No. We found no human studies that report treatment duration for FOXO4-DRI.
How much bacteriostatic water should be added to a FOXO4-DRI vial?
There is no compound-specific volume. The diluent volume only sets the concentration: concentration = mass in the vial ÷ volume added (for example, 10 mg in 2 mL gives 5 mg/mL). The calculator on this page shows the arithmetic for any combination.
How many units is a given amount on an insulin syringe?
On a U-100 syringe, 100 units = 1 mL. Units for an amount = amount ÷ (concentration per unit). The calculator converts any amount you enter at the concentration you choose; a unit is a volume mark, not an amount of compound.
Is FOXO4-DRI FDA-approved?
Not approved — research use only. Not approved by the FDA for any use, and no DailyMed drug label for it was found 3,4. No registered clinical trial of FOXO4-DRI was identified in a ClinicalTrials.gov search, which returned no studies for the term 5. It does not appear in any category of FDA's May 14, 2026 503A bulk drug substances list 6.

References

  1. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging Cell. 2017
  2. FOXO4-DRI (CID 168431240): molecular formula C228H388N86O64, molecular weight 5358 PubChem. 2026
  3. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging Front Aging. 2026
  4. DailyMed drug name search returned no labels for FOXO4 (searched 22 October 2026) DailyMed. 2026
  5. ClinicalTrials.gov search for "FOXO4-DRI" returned 0 studies (searched 22 October 2026) ClinicalTrials.gov. 2026
  6. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) FDA. 2026
  7. Cellular Senescence Contributes to the Progression of Hyperoxic Bronchopulmonary Dysplasia Am J Respir Cell Mol Biol. 2024
  8. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice Aging (Albany NY). 2020
  9. FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway Front Bioeng Biotechnol. 2025
  10. Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression Circulation. 2023
  11. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI Nat Commun. 2025
  12. Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline Naunyn Schmiedebergs Arch Pharmacol. 2026
  13. FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice Naunyn Schmiedebergs Arch Pharmacol. 2023
  14. FOXO4 as a Redox-Sensitive Regulator of Antioxidant Defense and Cellular Senescence: Cysteine-Based Signaling, p53 Interaction, and Therapeutic Targeting Antioxidants (Basel). 2026
  15. Targeting Multiple Homeostasis-Maintaining Systems by Ionophore Nigericin Is a Novel Approach for Senolysis Int J Mol Sci. 2022
  16. World Anti-Doping Code International Standard: Prohibited List 2026 WADA. 2026

Last reviewed October 22, 2026 by the Amiravo editorial team. Editorial policy · Report an error